Product
BMS-986315
Aliases
Anti-NKG2A
2 clinical trials
2 indications
Indication
Advanced Solid TumorIndication
NSCLCClinical trial
A Phase 1/2 Study of BMS-986315 as Monotherapy and in Combination With Nivolumab or Cetuximab in Participants With Advanced Solid TumorsStatus: Active (not recruiting), Estimated PCD: 2024-04-01
Clinical trial
A Randomized, Double-blind, Phase 2 Study of BMS-986315 and Nivolumab in Combination With Chemotherapy Versus Nivolumab in Combination With Chemotherapy as First-line Treatment for Participants With Stage IV or Recurrent Non-small Cell Lung Cancer (NSCLC)Status: Recruiting, Estimated PCD: 2026-10-10